Peak Bio, Inc. (PKBO)
OTCMKTS · Delayed Price · Currency is USD
0.180
+0.005 (2.86%)
At close: Sep 20, 2024

Peak Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
0.350.370.610.53-
Revenue Growth (YoY)
-24.30%-39.46%15.02%--
Cost of Revenue
0.721.633.927.1210.4
Gross Profit
-0.37-1.26-3.32-6.6-10.4
Selling, General & Admin
6.48.298.532.472.94
Operating Expenses
6.48.298.532.472.94
Operating Income
-6.77-9.55-11.85-9.07-13.34
Interest Expense
-2.44-2.73-0.05-0.01-0
Interest & Investment Income
00000
Other Non Operating Income (Expenses)
3.382.980.38--
EBT Excluding Unusual Items
-5.83-9.3-11.51-9.08-13.34
Asset Writedown
--3.51---
Other Unusual Items
1.21-0.02-1.650.87-
Pretax Income
-4.63-12.83-13.16-8.21-13.34
Income Tax Expense
---0.070.080.01
Net Income
-4.63-12.83-13.09-8.29-13.35
Net Income to Common
-4.63-12.83-13.09-8.29-13.35
Shares Outstanding (Basic)
23211817-
Shares Outstanding (Diluted)
23211817-
Shares Change (YoY)
18.70%19.56%3.20%--
EPS (Basic)
-0.20-0.61-0.74-0.48-
EPS (Diluted)
-0.20-0.61-0.74-0.48-
Free Cash Flow
-4.41-4.76-7.63-8.87-11.99
Free Cash Flow Per Share
-0.19-0.22-0.43-0.52-
Operating Margin
-1913.08%-2596.41%-1949.68%-1715.95%-
Profit Margin
-1307.10%-3486.47%-2153.88%-1569.65%-
Free Cash Flow Margin
-1245.00%-1293.37%-1255.24%-1679.72%-
EBITDA
-6.65-9.41-11.7-8.89-13.18
D&A For EBITDA
0.120.140.150.180.16
EBIT
-6.77-9.55-11.85-9.07-13.34
Revenue as Reported
0.350.370.610.53-
Source: S&P Capital IQ. Standard template. Financial Sources.